465 / 1498
Summary
• Between 10 and 40% of patients with HL fail after initial therapy.
• Patients failing after chemotherapy alone are candidates for salvage RT.
• IFRT/ISRT followed by TLI integrated with high-dose chemotherapy is an
effective, feasible and safe salvage therapy for patients with previously
unirradiated, relapsed/ refractory HL.
• On multivariate analysis, CR to standard-dose salvage chemotherapy is the
most important predictive factor for long-term OS, EFS and DSS after HDT.
• Primary refractory disease and extranodal disease at relapse are associated
with worse outcome.
• Long-term morbidity and second malignancy rates are relatively low.